In a report released on February 7, Maja Pataki from Kepler Capital maintained a Hold rating on Qiagen (QGEN – Research Report), with a price target of €39.18. The company’s shares closed yesterday at $44.12.
Pataki covers the Healthcare sector, focusing on stocks such as Qiagen, Tecan Group AG, and Demant. According to TipRanks, Pataki has an average return of -15.3% and a 31.79% success rate on recommended stocks.
In addition to Kepler Capital , Qiagen also received a Hold from UBS’s John Sourbeer in a report issued on February 7. However, on the same day, Deutsche Bank maintained a Buy rating on Qiagen (NYSE: QGEN).
See the top stocks recommended by analysts >>
The company has a one-year high of $49.85 and a one-year low of $34.77. Currently, Qiagen has an average volume of 1.3M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Qiagen (QGEN) Company Description:
QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.
Read More on QGEN:
